<DOC>
	<DOCNO>NCT00950989</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled study subject RA inadequate response methotrexate .</brief_summary>
	<brief_title>AMG 827 Rheumatoid Arthritis Subjects With Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Active RA least 6 month Current RA define ≥ 6 swollen joint ( 66 joint examine ) ≥ 8 tender/painful joint ( 68 joint examine ) screen baseline ( swollen tender/painful joint count must include distal interphalangeal joint ) least 1 follow screening : Erythrocyte sedimentation rate ≥ 28 mm Creactive protein &gt; 15 mg/L At least 1 follow screening : Rheumatoid factor positive Anticyclic citrullinated peptide antibody positive Currently take methotrexate ≥ 12 week stable dose methotrexate 15 25 mg weekly ≥ 4 week day 1 . Prosthetic joint infection within 5 year screen native joint infection within 1 year screen Class IV RA Felty 's syndrome Presence serious infection Significant concurrent medical condition Pregnant breast feeding Significant Laboratory abnormalities Any DMARD methotrexate within 28 day Leflunomide live vaccine within 3 month Previous use experimental commercially available biologic DMARD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Rheumatic Diseases</keyword>
</DOC>